IC50 values of trisindoline 3 against cancer and normal cell linesa.
| Cancer/tumor cell lines | IC50 | References | ||
|---|---|---|---|---|
| Trisindoline 3 | Etoposide (standard) | Doxorubicin (standard) | ||
| HCT-15 | 6.63 ± 0.43 μM | 1.42 ± 0.02 μM | 9 | |
| HCT-15/CL02 | 5.11 ± 0.44 μM | 11.68 ± 2.38 μM | 9 | |
| MES-SA | 3.51 ± 0.03 μM | 0.28 ± 0.02 μM | 9 | |
| MES-SA/DX5 | 5.50 ± 0.53 μM | 8.14 ± 0.89 μM | 9 | |
| A549 | 18.4 μM | 19 | ||
| 8.6 μM | 8 | |||
| 1.23 ± 0.030 μM | 15.07 ± 0.13 μM | 7 | ||
| SK-N-SH | 11.3 μM | 8 | ||
| 0.90 ± 0.06 μM | 0.97 ± 0.03 μM | 7 | ||
| HL-60 | 5.70 μg mL−1 | 22 | ||
| Bel-7402 | 6.85 μg mL−1 | 22 | ||
| MCF-7 | 49.8 μM | 8 | ||
| Hep G-2 | 20.4 μM | 8 | ||
| DU-145 | 8.7 μM | 8 | ||
| MDA-MB | Inactive | 8.14 ± 0.14 μM | 7 | |
| MRC-5 | >100 μM | 14.84 ± 0.25 μM | 7 | |
a
HCT-15: colorectal adenocarcinoma; HCT-15/CL02: multidrug-resistant colorectal adenocarcinoma; MES-SA: uterine sarcoma; MES-SA/DX5: multidrug-resistant uterine sarcoma; A549: lung cancer; SK-N-SH: neuroblastoma or central nerve system (CNS) cancer; HL-60: promyelocytic leukemia; Bel-7402: hepatocellular carcinoma; MCF-7: breast cancer; Hep G-2: liver cancer, DU-145: prostate cancer, MDA-MB: breast cancer; MRC-5: human normal lung.